Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Closed	no age specified	NCI	SWOG-7736

Objectives

I.  Determine the efficacy of anguidine in treating the major urological 
malignancies in terms of response rate, duration of responses and survival.
II.  Study the adverse effects of anguidine and factors important in producing 
such effects.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with measurable lesions of 
histologically confirmed advanced urological malignancies including those of 
bladder, prostate, testes, renal pelvis or renal cell carcinoma not eligible 
for higher priority therapy.  Patients must have a life expectancy of 6 weeks, 
a performance status of at least 3, have had no chemotherapy or radiation for 
3 weeks, and must have stopped hormonal therapy if given for renal cell 
cancer.  Wbc above 4000, platelet count about 100,000, serum bilirubin less 
than 6.0, serum creatinine less than 2.0 mg/dl, and BUN less than 40 mg/ml, 
are required.  Poor-risk patients are those more than 65 years old, with poor 
tolerance to prior chemotherapy, with liver or bone marrow involvement, or 
bilirubin about 3.0, or hepatic enzymes 3 or more times normal, or with 
extensive radiotherapy to myeloproliferative areas.

Expected Enrollment

Protocol closed 03/79.

Outline

Nonrandomized study.  Single-agent Chemotherapy.  Anguidine, ANG, NSC-141537.

Trial Contact Information

Trial Lead Organizations

Southwest Oncology Group

Charles Coltman, MD, Protocol chair(Contact information may not be current)		Ph: 210-567-2710